anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject promoter useful for treating breeding disorders, diarrhea, etc., of domestic animals, having excellent growth promoting action on animal tissual cell and pituitary stimulating activity, comprising RU substance, a substance produced from a fungus belonging to the genus Rhizopus. CONSTITUTION:The objective promoter comprising RU substance, a substance produced from a fungus (e.g. FERM-P 3,646) belonging to the genus Rhizopus, having the following characteristics. A composition in a state of 41.8% water content, 21.5% amino state nitrogen compound, 33.0% saccharide and 3.4% ash. Infrared absorption spectrum: existence of CO-NH, COOH and C-OH is recognized. Solubility in solvents: soluble in water and slightly soluble in alcohol. pH stability: stable at pH 2-12. Temperature stability: stable in treatment at 100-120 deg.C for 30 minutes. Color tone of aqueous solution: colorless-light brown. Physiological activity: having pituitary stimulating activity. The promoter, for example, is obtained by culturing a fungus such as Rhizopus U-1 belonging to the genus Rhizopus, capable of producing RU substance, in a common medium under an aerobic condition at 26-28 deg.C for 3-10 days.
PURPOSE:To improve adsorptivity of an adsorbent to P and P-compds. and to eliminate acute toxicity when it is administrated by 5,000mg/kg orally to Jcl-SD rat by prepg. the adsorbent with an MgO-TiO2 compound having a specific compound ratio. CONSTITUTION:Precipitate is obtd. by a disproportionation precipitation, etc., wherein a mixture of MgCl2 and TiCl4 in a specified proportion is hydrolyzed with aq. NH3, and the precipitate is calcined. Suitable calcination temp. is usually 200-1,000, pref. 300-700 deg.C. Obtd. MgO-TiO2 compound has a compsn. corresponding to 99.99/0.01-80/20 proportion of MgO/TiO2 (expressed in terms of molar ratio) and 50-700m<2>/g specific surface area (BET method), having a crystal structure corresponding to a crystal pattern of MgO in accordance with the powder X-ray diffraction method. When the compound material is used for adsorbent, P and P compds. are adsorbed with extremely good result.
Acute kidney injury (AKI) is a common problem encountered in the intensive care unit (ICU), estimated to occur in up to 60% of all critically ill patients, depending on the definition. Recent large randomized clinical trials in critical care nephrology have focused on the optimal timing of initiation of acute kidney replacement therapy (KRT). However, less is known about the ideal circumstances in which KRT may be successfully discontinued. KRT is a complex and expensive therapy, with complications including catheter-associated infections, hemorrhage, hemodynamic instability, and potential delayed renal recovery.

The novel serum-biomarker proenkephalin A 119-159 (penkid) is a stable fragment derived from the precursor enkephalins, which are known as small endogenous opioid peptides and are produced throughout the human body, including the kidneys. Plasma concentrations of penkid have been found to be strongly negatively correlated with measured glomerular filtration rate. Whether penkid may have a role in initiation and discontinuation of KRT remains unknown.
BACKGROUND: Epididymal tumors, especially malignant tumors, have low incidence and are rare in our clinical work. However, they may progress quickly and have poor prognosis. For such rare clinical cases with extremely low incidence rates, and as they are prone to misdiagnosis and missed diagnosis and have a very poor prognosis, clinical workers need to pay special attention and consider the possibility of primary epididymal malignant tumors.
CASE REPORT: A 63-year-old Chinese male patient from Asia was admitted due to scrotal pain. Upon examination, an abnormal lesion was found in the right epididymal region. After thorough evaluation, surgical resection was performed, and the postoperative pathological result confirmed the presence of epididymal adenocarcinoma. After further ruling out secondary lesions, primary epididymal adenocarcinoma was considered. Right retroperitoneal lymph node dissection was performed under laparoscopic for treatment, and 1/11 lymph node metastasis was detected after surgery. The patient is currently under close follow-up.
CONCLUSIONS: The number of clinical cases of primary epididymal malignant tumors is very limited, there is currently no standardized diagnosis and treatment process, and there is a lack of systematic evaluation methods regarding the effectiveness of different treatment options such as chemotherapy, radiotherapy, immunotherapy, and targeted therapy. In addition, the outcome is difficult to predict. In this article, we reviewed relevant literature and systematically elaborated on the diagnosis and treatment of epididymal malignant tumors, hoping to provide useful information for relevant experts.
Irinotecan hydrochloride injection, USP is available in single-dose amber glass vials in the following package sizes:

2mL NDC 72485-211-02

Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature]. Protect from light. Protect from freezing. Keep the vial in the carton until the time of use.

Inspect the vial for damage and visible signs of leaks before removing from the carton. If damaged, incinerate the unopened package.
Orofacial pain (OFP) induced by temporomandibular disorders (TMDs) is prevalent, affecting approximately 4.6 % of the population. One specific type of TMD is temporomandibular osteoarthritis (TMJOA), a common degenerative disease that significantly impacts patients' quality of life. Differentially expressed circular RNAs (DEcircRNAs) in the thalamus, which serves as a relay station in the orofacial pain transmission pathway, may play a crucial role and serve as potential target markers for inflammation and the progression of inflammatory pain in TMJOA. The aim of this study was to investigate the expression profile of circRNAs in the thalamus of TMJOA. We obtained the circRNA expression profile from the thalamus of a rat model of TMJOA through high-throughput sequencing (HT-seq) and further validated their expression using reverse transcription real-time polymerase chain reaction (RT-qPCR), followed by bioinformatics analysis of the expression data. A total of 425 circRNAs (DESeq2 p- value < 0.05, |log2FoldChange| > 0.0) were identified as significantly differentially expressed by RNA-Seq, comprising 188 up-regulated and 237 down-regulated circRNAs. After validation via RT-qPCR, we employed miRanda software to predict the binding sites of miRNAs for the identified circRNAs to further explore the functions of DEcircRNAs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses revealed that DEcircRNAs were primarily enriched in pathways and functions related to synapse development, protein signaling and modification, 'Circadian entertainment', the 'MAPK signaling pathway', and 'Glutamatergic synapse'. These findings suggest that DEcircRNAs in the thalamus play a significant role in the progression of TMJOA and may serve as promising candidate molecular targets for gene therapy.
One of the central nervous system's most frequent diseases is Parkinson's disease (PD). In individuals with PD upper limb impairments could be present such as resting tremor or micrographia, often the first symptom of the disorder. These upper limb conditions can lead to difficulties in work, leisure, and everyday activities such as eating and dressing as the disease advances. This research was aimed to provide insightful information for both clinicians, researchers and for community in general. This study was helpful in the field of neurorehabilitation to bridge the gaps of previous researches. Clinician or neurorehabilitation expert can apply the more useful technique on patients and get the better results in less time. Researchers can find the high-quality clinical evidence regarding constraint induced movement therapy on Parkinson's patients. According to evidence-based practice patient preference is considered in providing treatments to patients. So, patient can find out which treatment is better.

40 patients who fulfill the inclusion criteria were enrolled in this study. Written informed consent was taken from every subject participating in this study. Allocation of subjects in two groups was done by random number table. Group A was treated with Constrained Induced movement therapy along with routine physical therapy and group B was treated only with routine physical therapy. In routine physical therapy group patients received intervention according to systematic review and clinical guidelines that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function.39 Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool-down phase (in seating position): respiratory exercises and mobilization.

40 The routine or baseline therapy was remained same throughout the study. Constraint induced movement therapy was given to group A for four weeks. Training was done for 6 hrs/day, 5 days/week for 4 weeks. All the information wascollected by using standardized questionnaire of Frenchay arm test. Confounding variables were controlled by randomization and restriction methods. All treatment was given by single therapist to control the biasness.
The invention relates to compound dipyridamole/aspirin sustained-release capsules and a preparation technique thereof. The invention is characterized in that sustained-release mircropill technique is applied to prepare two components: sustained-release dipyridamole and quick acting aspirin into compound preparation which is used for treating cardiovascular and cerebrovascular diseases. Different dosage at different times and multiple taking of the two medicines are changed into twice a day, thereby being convenient for the patient to take. Aspirin can reduce the dosage of dipyridamole and reduce the side effect thereof of blood pressure decrease; dipyridamole can improve the bioavailability of aspirin, and increase the efficacy on preventing and treating cardiovascular and cerebrovascular diseases. By combining dipyridamole and aspirin, the effects of the two medicines on inhibition of platelet aggregation and thrombosis in different links can be completely exerted. The efficacy of the compound preparation is obviously superior to that of single prescription preparation.
Standard automated perimetery is considered the gold standard for evaluating a patient's visual field. However, it is costly and requires a fixed testing environment. In response, perimetric devices using virtual reality (VR) headsets have emerged as an alternative way to measure visual fields in patients. This systematic review aims to characterize both novel and established VR headsets in the literature and explore their potential applications within visual field testing. A search was conducted using MEDLINE, Embase, CINAHL, and the Core Collection (Web of Science) for articles published until January 2023. Subject headings and keywords related to virtual reality and visual field were used to identify studies specific to this topic. Records were first screened by title/abstract and then by full text using predefined criteria. Data was extracted accordingly. A total of 2404 records were identified from the databases. After deduplication and the two levels of screening, 64 studies describing 36 VR headset perimetry devices were selected for extraction. These devices encompassed various visual field measurement techniques, including static and kinetic perimetry, with some offering vision rehabilitation capabilities. This review reveals a growing consensus that VR headset perimetry devices perform comparably to, or even better than, standard automated perimetry. They are better tolerated by patients in terms of gaze fixation, more cost-effective, and generally more accessible for patients with limited mobility.
The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance.  Such active domains are determined by substituting selected amino acid segments of the polypeptide with an analogous polypeptide segment from an analog to the polypeptide. The analog has a different activity with the target substance as compared to the parent polypeptide. The activities of the segment-substituted polypeptide are compared to the same activity for the parent polypeptide for the target. A comparison of such activities provides an indication of the location of the active domain in the parent polypeptide. The invention also provides methods for identifying the active amino acid residues within the active domain of the parent polypeptide. The method comprises substituting a scanning amino acid for one of the amino acid residues within the active domain of the parent polypeptide and assaying the residue-substituted polypeptide so formed with a target substance. The invention further provides polypeptide variants comprising segment-substituted and residue-substituted growth hormones, prolactens and placental lactogens.
All patients randomly allocated to this arm will have their stools tested using a PCR-based molecular assay that can simultaneously test for 22 different infectious pathogens with a turnaround time of approximately 1 hour. As results become available, they will be available for review by the patient's healthcare providers in the electronic medical record.
PROBLEM TO BE SOLVED: To obtain a composite material excellent in transparency, dispensability into a base material and defensive ability against UV in a region of B wave length by incorporating titanium oxide into a silica carrier consisting essentially of silicon oxide. SOLUTION: This composite material preferably consists of plural particulate particles of titanium oxide generally uniform densely scattered in a silica carrier. The concentration of added titanium oxide to a mass of whole powder is preferably 0.5-90%. The composite material is produced by adding liquid in which particulates of titanium oxide are dispersed (e.g. titania sol) to liquid in which particulates of silicon oxide are dispersed (e.g. silica sol) and occluding and compounding titanium oxide when silicon oxide is deposited. Silicon oxide is deposited on a specified condition to obtain meso porous powder or bar- shaped meso porous powder whose meso pores have 20-200 nm outside diameter and longitudinally extend.
PROBLEM TO BE SOLVED: To obtain a treated powder excellent in water repellency and dispersibility and a powdery cosmetic material contg. no oil by coating the surface of a powder with a silicone compd. having SiH groups and adding an SiH-reactive compd. to the parts of unreacted SiH groups of the silicone compd. in a specified density. SOLUTION: At least one powder having a particle size of 10 μm or lower and selected from among org. and inorg. pigments, metal oxides and hydroxides, mica, pearlescent materials, metals, etc., is used. It may be in the form of agglomerates or moldings. A superfine powder having a particle size of 0.02 μm or lower can be modified, too. Among silicone oils, silicone resins, silicon waxes, etc., a compd. represented by the formula (R<1> to R<3> are each H or a hydrocarbon group optionally halogenated; R<4> to R<6> are each H, etc.; a is 1 or higher; b is 0, 1, or higher; c is O or 2 provided 3<=a+b+c<=10,000; and there is at least one SiH group) is suitable as the silicone compd. An SiH- reactive compd. in an amt. of 100 μmol (based on 1 g of the powder) is added to the silicone compd.
Control group receiving the standard of care for skin grafts. Control Group-will remove gauze dressing post operative day 2 but leave adeptic. Donor site will be cleaned daily with soap and water. Gauze applied daily as needed for drainage and will be stopped when drainage stops. The adeptic, which forms a biologic dressing, will be removed by the patient over time as it lifts from the wound.
PURPOSE:To provide a hair treatment excellent in transparency and stability with time and having a uniform conditioning effect on the hair. CONSTITUTION:This hair treatment contains a cationized guar gum synthesized by introducing a quaternized nitrogen-containing group into guar gum and another cationic polymer, e.g. a cationized cellulose derivative or a copolymer of a diallyl quaternary ammonium salt and acrylamide preferably in a ratio of 4:1 to 1:4. If 0.5 to 20wt.% polyhydric alcohol such as propylene glycol or 1,3-butylene glycol is blended with this treatment, effects such as improvement of transparency prevention of generation of precipitate with time and improvement of a conditioning effect are obtained. In addition, if an anionic surfactant and an amphoteric surfactant such as a compound of formula I (R<1> is a 8 to 20C alkyl or alkenyl; R<2> and R<3> are each a 1 to 3C alkyl) or a compound of formula II (R<8> is a 7 to 19C alkyl or alkenyl; M is H or an alkaline metal) are blended in an amount of 5 to 40wt.% in total, fingers can be run more smoothly through the hair in washing of the hair. The finished result, etc., is also improved.
A compress bandaging belt for medical use is provided in this utility model. A compress cloth comprises an outer cladding [1], an isolation layer [2] and a drug supporting layer [3]. A fixation band is fixedly connected on one side of the compress cloth. A length regulating segment [4], an elastic stretching segment [5] and a hair clamping segment [6] are provided on the fixation band. A hair clamp which matches with the hair clamping segment [6] of the fixation band correspondingly is provided on the outward face of the outer cladding [1] of the compress cloth. The compress bandaging belt for medical use has the advantages of reasonable design, simple structure, which can satisfy the needs of different position or patients in different ages. Ointment is isolated without extravasations to prevent drug from loss and pollution, thus compress bandaging effect is improved. Operation of compress bandaging is convenient, rapid, and can be used repeatedly, thus the compress bandaging belt for medical use is a novel and practical compress bandaging band.
On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures.
The purpose of this research study is to test the protection of volunteers previously vaccinated with Tetravalent Dengue Virus (TDEN) Purified Inactivated Vaccine (PIV) with alum and boosted with TDEN live attenuated vaccine (LAV) formulation against a weakened form of an experimental dengue virus challenge. The Investigators will also include people that have not received the study vaccine. The Investigators are collecting information about how the vaccine protects against a dengue virus challenge as well as adding to knowledge about the safety of the challenge. The information will help Investigators develop vaccines to protect people from dengue. Participation is voluntary. The duration of participation will last for 180 days (six months). After participants are exposed to the weakened dengue virus, the Investigators will follow them closely to measure their symptoms. Like the flu, participants might expect to have a headache, rash, body aches, fever and chills or they may experience no symptoms whatsoever. If a participant does develops symptoms, the Investigators will monitor him/her closely in a local hotel or a wing of our hospital to ensure safety and to treat symptoms if they occur. Participants will be compensated for their time.
Healthy subjects who have been genotyped for CYP2C19\*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 intermediate metabolizers (IM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, "Pharmacogenetics of Anti-platelet Intervention" (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
The invention discloses antibacterial peptides LI7, LI14 and LI21 and derivatives and application thereof, and in vitro and in vivo studies show that LI14 has good antibacterial effect on various gram-positive and gram-negative bacteria and drug-resistant bacteria thereof, wherein the minimum inhibitory concentration on methicillin-resistant staphylococcus aureus and multi-drug-resistant escherichia coli is 4 mug/mL. Meanwhile, the LI14 has good bactericidal activity on bacteria in different metabolic states, including biomembranes and retention bacteria. The synergistic antibacterial activity shows that LI14 has remarkable synergistic antibacterial activity with different antibiotics. In vitro and in vivo safety indicates that LI14 has no toxic side effects below the tested dose. The experiment of infection of greater wax moth shows that LI14 can significantly improve the survival rate of greater wax moth; the experiment of rat skin wound infection shows that LI14 can effectively promote wound healing. The research shows that the antibacterial peptide LI series compounds are novel antibiotic candidates with great potential.
A device and method in which cells of a heterogeneous population are separated through a column partially packed with antibody coated beads. The antibody coated beads may be placed in a gradient fashion such that each layer binds to and selects a subset of cells from the entire sample population. A lipoaspirate fluid, or other fluid containing cells, may be brought through the column by positive pressure on the specimen bag side and negative pressure at the base of the column with a vacuum line and waste trap. The column may then be inverted and irrigated internally with a wash buffer to remove unhomogenized macroscopic tissue material and unbound residual cells. The column may be closed at the ends and shaken and/or washed with an enzymatic buffer. Cells may be removed from the device with an elution buffer.
This invention relates to stable pharmaceutical compositions of 5,10-methylene-(6R)-, -(65)- or -(6R,S)-tetrahydrofolate (MTHF), by adjusting to a basic pH and the simultaneous use of citrate. Stabilisation is effected even in the absence of a reducing agent. The present invention is particularly suitable for producing lyophilisation solutions and lyophilisates or dry powders and dry mixtures, since the stable MTHF solutions can be used in high concentrations for filling corresponding vessels such as vials, ampoules, etc. The lyophilisates have a surprisingly long shelf life and are surprisingly stable. They can be reconstituted without problems by adding water or aqueous solutions, and the final clear injection solutions again exhibit excellent stability properties. Moreover, the present invention even makes it possible to prepare difficultly soluble calcium 15 or acidic salts of MTHF in high concentrations and as physiologically compatible isotonic solutions.